KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance).

L Dercle, S Geyer, A B Nixon, F Innocenti, Q Shi, S B Jacobson, L Luk, A Liu, H Yang, Y Wen, B Zhao, T Eche, F-Z Mokrane, M Yang, J Meyerhardt, E M O'Reilly, A P Venook, A B El-Khoueiry, L H Schwartz, G K Abou-Alfa

ESMO Open 10(12) 105848

PMID41337859
PMCIDPMC12720083
DOI10.1016/j.esmoop.2025.105848
发表日期2025-12-03
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: Current methods to evaluate therapeutic response in patients with hepatocellular carcinoma (HCC) rely on tumor size and density, which do not always correlate well with survival. We used pretreatment clinical and radiomics variables to predict overall survival (OS) in the randomized phase III CALGB 80802 (Alliance) trial, investigating the efficacy of sorafenib + doxorubicin versus sorafenib alone. MATERIALS AND METHODS: Using machine learning, we analyzed baseline and first follow-up computed tomography (CT) images and associated clinical metadata from patients imaged in February 2010-May 2015, up to November 2015 with follow-up. Adult patients with HCC (n = 129) were randomly assigned to training (n = 92) and validation (n = 37) sets. We assessed the performance of a signature combining CT imaging features and clinical variables using hazard ratios to estimate OS after week 10 (first follow-up). RESULTS: Most patients were male (86.6%) and had bilirubin <2 mg/dl (98.4%), albumin >3.5 g/dl (69.0%), and moderately differentiated HCC (34.1%). Median (interquartile range) age: 58 years (63-71 years), alpha-fetoprotein (AFP): 2.5 ng/ml (26-282 ng/ml), international normalized ratio: 1 (1.1-1.2), Child-Pugh score: 5 (5-6). The highest-performing parsimonious training set signature combined clinical and radiomics features at baseline and week 10. In the validation set, the hazard ratio was 2398 (95% confidence interval 121-47 371) (P < 0.001). The signature's variables, ranked by importance, included baseline clinical features [albumin (1), AFP (2), Child-Pugh (4)], baseline radiomics features [component 17 (3), component 1 (5), component 9 (7), tumor volume (8)], and week 10 radiomics features [delta tumor volume (6)]. CONCLUSION: OS can be accurately predicted in patients with HCC receiving sorafenib by combining certain radiomics features with clinical metadata, centered primarily on baseline characteristics.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 3

Figure 3 Association of RadSig1 with OS landmarked at 10-week follow-up. Each signature’s output was an individualized estimation and a continuous value ranging from 0 to 1 (from most to least favorable estimated OS). The analysis of median OS in our study revealed distinct outcomes across quartiles (log-rank, P < 0.0001). The median OS for the overall cohort was 13.5 months (95% CI 6.1-20.9 months), with the first quartile reaching 17.8 months (95% CI 7.1-28.5 months), the second quartile at 15.0 months (95% CI 10.0-20.1 months), the third quartile at 5.6 months (95% CI 3.0-8.2 months), and the fourth quartile exhibiting a markedly lower median OS of 1.3 months (95% CI 0.0-3.5 months). CI, confidence interval; OS, overall survival.

Kaplan-Meier_estimate_of_OS_in_the_validation_set

OS

Figure 3 · Panel Kaplan-Meier_estimate_of_OS_in_the_validation_set

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel Kaplan-Meier_estimate_of_OS_in_the_validation_set 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Radiomics pipeline. 2D, two-dimensional; 3D, three-dimensional; AFP, alpha-fetoprotein; CRC, colorectal cancer; CT, computed tomography; HCC, hepatocellular carcinoma; INR, international normalized ratio; NSCLC, non-small-cell lung cancer; OS, overall survival.
非 KM Figure
Figure 2Figure 2 Importance of variables combined in RadSig1. Variable importance in the random forest for estimation of OS using RadSig1. The variables (rank of importance) selected in the best signature included baseline clinical features [albumin (1), AFP (2), Child–Pugh score (4)], baseline radiomics features [component 17 (3), component 1 (5), component 9 (7), delta tumor volume/burden (8)], and week 10 radiomics features [delta tumor volume/burden (6)]. Of note, baseline clinical and radiomics variables are majority and have a higher importance. AFP, alpha-fetoprotein; OS, overall survival.
非 KM Figure